Our results demonstrate that inhibition of me-BAF155 leads to decreased expression of SE-regulated oncogenes, activation of ISGs in tumor cells, as well as enhanced CD8+ T cell infiltration and cytotoxicity. This evidence concerns the gene SMARCC1 and neoplasm.